Penny Pinnock, Siemens Financial Services, explores how more efficient and accurate technology is contributing to improved healthcare outcomes and helping private hospital groups cope with supporting NHS backlog.
Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company for select ASEAN markets.
Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimised to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
Cognizant have announced an expanded agreement with Takeda a global biopharmaceutical company, to support the company’s digital transformation strategy by reinforcing and supporting its technology efforts.
Gerresheimer, a manufacturer for the pharma and life science industry, will invest more than $88 million in expanding its manufacturing operations in Peachtree City, creating over 200 new jobs for Fayette County.
Futura Medical plc has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health to commercialise Eroxon, the Company's topical, gel-based Erectile Dysfunction treatment.
EirGen Pharma has announced the commencement of works in its new plant in the IDA Industrial Estate, including a €20 million internal refit and additional Plant rooms expanding its Oral Solid Dose manufacturing and packaging capabilities.
Isomorphic Labs have announced that it has entered into a strategic research collaboration with Eli Lilly and Company and a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
WuXi AppTec have announced the commissioning of two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.
Novartis recently announced that it has received approval from the US FDA for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
As we move into 2024, life sciences real estate managers will need to consider sustainability, funding, investor consolidation, and planning regulations as top priorities.
Shionogi B.V., the European subsidiary of SHIONOGI & Co., Ltd. have announced that they have signed a distribution agreement with Swedish Orphan Biovitrum AB, Sobi, for Fetcroja covering 13 countries in Central & Eastern Europe.
